British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has bought its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for greater than $1 billion, the Occasions reported Sunday.
What Occurred: AstraZeneca disposed of its stake in Moderna following the U.S. biotechnology firm’s coronavirus vaccine breakthrough, in keeping with the Occasions report. It is not clear over what interval AstraZeneca bought its holding, the report added.
The information of the stake sale comes simply as Johnson & Johnson’s (NYSE: JNJ) single-shot coronavirus vaccine candidate acquired approval because the third vaccine for emergency use within the U.S.
Moderna’s coronavirus vaccine was permitted by U.S. regulators in December final 12 months for emergency use in opposition to COVID-19. Whereas reporting its fourth-quarter monetary leads to late February, Moderna mentioned it expects product gross sales of $18.4 billion from the vaccine this 12 months.
Why It Issues: AstraZeneca’s 7.7% stake made it the second-largest investor in Moderna